ID: ALA1790587

Max Phase: Preclinical

Molecular Formula: C29H43N5O7

Molecular Weight: 573.69

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC[C@@H](C)[C@@H]1NC(=O)[C@@H](Cc2ccc(OC)cc2)NC(=O)[C@H](CCCCCC(=O)NO)NC(=O)[C@H]2CCCN2C1=O

Standard InChI:  InChI=1S/C29H43N5O7/c1-4-18(2)25-29(39)34-16-8-10-23(34)28(38)30-21(9-6-5-7-11-24(35)33-40)26(36)31-22(27(37)32-25)17-19-12-14-20(41-3)15-13-19/h12-15,18,21-23,25,40H,4-11,16-17H2,1-3H3,(H,30,38)(H,31,36)(H,32,37)(H,33,35)/t18-,21+,22-,23-,25+/m1/s1

Standard InChI Key:  NXTMDUWTQZXRRK-SIZHRBNOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 573.69

Molecular Weight (Monoisotopic): 573.3162

AlogP: 1.20

#Rotatable Bonds: 11

Polar Surface Area: 166.17

Molecular Species: NEUTRAL

HBA: 7

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 8.90

CX Basic pKa:

CX LogP: 1.13

CX LogD: 1.11

Aromatic Rings: 1

Heavy Atoms: 41

QED Weighted: 0.15

Np Likeness Score: 0.90

References

1. Nishino N, Yoshikawa D, Watanabe LA, Kato T, Jose B, Komatsu Y, Sumida Y, Yoshida M..  (2004)  Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.,  14  (10): [PMID:15109626] [10.1016/j.bmcl.2004.03.018]

2. Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, Verdin E, Jung M..  (2004)  Subtype selective substrates for histone deacetylases.,  47  (21): [PMID:15456267] [10.1021/jm0497592]

3. Banerjee S, Adhikari N, Amin SA, Jha T..  (2019)  Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.,  164  [PMID:30594678] [10.1016/j.ejmech.2018.12.039]

Source

Source(1):

• Scientific Literature